← back to search

Meinhard Kieser

Heidelberg University · DE
Area of research
Statistics and Probability · Management Science and Operations Research
Research interest
Research interests include Statistical Methods in Clinical Trials, Optimal Experimental Design Methods, Health Systems, Economic Evaluations, Quality of Life, and Advanced Causal Inference Techniques.
h-index
61
citations
13,708
works
549
NIH funding
primary concept
email

Recent publications

Hypofractionated stereotactic radiotherapy versus whole-brain radiotherapy following brain metastasis resection: Results of the ESTRON randomized phase 2 trial
Neuro-Oncology 2025cited by 3position: middledoi
Stereotactic radiosurgery for 1–10 brain metastases to avoid whole-brain radiotherapy: Results of the CYBER-SPACE randomized phase 2 trial
Neuro-Oncology 2024cited by 17position: middledoi
Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction
JAMA Network Open 2024cited by 10position: middledoi
Bright light therapy versus physical exercise to prevent co-occurring depression in adolescents and young adults with attention-deficit/hyperactivity disorder: a multicentre, three-arm, randomised controlled, pilot phase-IIa trial
European Archives of Psychiatry and Clinical Neuroscience 2024cited by 3position: middledoi
Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive post-remission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia
Haematologica 2024cited by 1position: middledoi
Outcome analysis for patients with subarachnoid hemorrhage and vasospasm including endovascular treatment
Neurological Research and Practice 2023cited by 11position: middledoi
Stereotactic Radiotherapy vs. Whole Brain Radiation Therapy for Patients with 1-10 Brain Metastases from Small Cell Lung Cancer: Results of the Randomized ENCEPHALON (ARO 2018-9) Trial
International Journal of Radiation Oncology*Biology*Physics 2023cited by 9position: middledoi
Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD
Trials 2023cited by 4position: middledoi
Using real‐world data to predict health outcomes—The prediction design: Application and sample size planning
Biometrical Journal 2023cited by 1position: lastdoi
Effect of Early vs Standard Approach to Tracheostomy on Functional Outcome at 6 Months Among Patients With Severe Stroke Receiving Mechanical Ventilation
JAMA 2022cited by 107position: middledoi
Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial
BMC Cancer 2022cited by 17position: middledoi
Neoadjuvant irradiation of extremity soft tissue sarcoma with ions (Extrem-ion): study protocol for a randomized phase II pilot trial
BMC Cancer 2022cited by 6position: middledoi
Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Clinical Cancer Research 2021cited by 41position: middledoi
The role of combined ion-beam radiotherapy (CIBRT) with protons and carbon ions in a multimodal treatment strategy of inoperable osteosarcoma
Radiotherapy and Oncology 2021cited by 29position: middledoi
Optimal planning of adaptive two‐stage designs
Statistics in Medicine 2021cited by 17position: lastdoi
Neoadjuvant irradiation of retroperitoneal soft tissue sarcoma with ions (Retro-Ion): study protocol for a randomized phase II pilot trial
Trials 2021cited by 15position: middledoi
FASTER and SCOTT&EVA trainings for adults with high-functioning autism spectrum disorder (ASD): study protocol for a randomized controlled trial
Trials 2021cited by 15position: middledoi
Glioblastoma radiotherapy using Intensity modulated Radiotherapy (IMRT) or proton Radiotherapy—GRIPS Trial (Glioblastoma Radiotherapy via IMRT or Proton BeamS): a study protocol for a multicenter, prospective, open-label, randomized, two-arm, phase III study
Radiation Oncology 2021cited by 13position: middledoi
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML
Trials 2021cited by 7position: middledoi
Glioblastoma Radiotherapy Using Intensity Modulated Radiotherapy (IMRT) or Proton Radiation - GRIPS Trial (Glioblastoma Radiotherapy via IMRT or Proton BeamS): A Study Protocol for a Multicenter, Prospective, Open-label, Randomized, Two-arm, Phase III Study.
Research Square 2021cited by 0position: middledoi
Why do you need a biostatistician?
BMC Medical Research Methodology 2020cited by 30position: lastdoi
Carbon ion radiotherapy as definitive treatment in non-metastasized pancreatic cancer: study protocol of the prospective phase II PACK-study
BMC Cancer 2020cited by 20position: middledoi
A new conditional performance score for the evaluation of adaptive group sequential designs with sample size recalculation
Statistics in Medicine 2020cited by 14position: middledoi
Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial
Trials 2020cited by 13position: middledoi
Durvalumab in frail and elder patients with stage four NSCLC: Study protocol of the randomized phase II DURATION trial
Research Square 2020cited by 0position: middledoi
Association of General Anesthesia vs Procedural Sedation With Functional Outcome Among Patients With Acute Ischemic Stroke Undergoing Thrombectomy
JAMA 2019cited by 291position: middledoi
Refining scores based on patient reported outcomes – statistical and medical perspectives
BMC Medical Research Methodology 2019cited by 63position: middledoi
Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial
BMC Cancer 2019cited by 36position: middledoi
Safety and efficacy of artesunate-amodiaquine combined with either methylene blue or primaquine in children with falciparum malaria in Burkina Faso: A randomized controlled trial
PLoS ONE 2019cited by 21position: middledoi
Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study
Radiation Oncology 2019cited by 15position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jürgen Debus · NYU Langone Health14 papers (2015–2024)Adriane Hommertgen · Heidelberg University9 papers (2018–2022)Johannes Krisam · Boehringer Ingelheim (Germany)9 papers (2018–2024)Geraldine Rauch · Charité - Universitätsmedizin Berlin9 papers (2013–2021)Klaus Herfarth · Universitätsklinik für Strahlentherapie7 papers (2019–2022)Stefan Rieken · University Medical Center7 papers (2018–2025)Laila König · Heidelberg University7 papers (2018–2025)Christina Klose · Zimmer Biomet (Netherlands)7 papers (2014–2019)Denise Bernhardt · TUM Klinikum6 papers (2018–2025)Rami A. El Shafie · University Medical Center6 papers (2018–2025)Thomas Welzel · Heidelberg University6 papers (2018–2025)Farastuk Bozorgmehr · University Hospital Heidelberg6 papers (2019–2025)Daniela Schmitt · University Medical Center6 papers (2018–2025)Michael Thomas · Barwon Health5 papers (2018–2024)Angela Paul · Heidelberg University5 papers (2018–2025)Kristin Lang · Heidelberg University5 papers (2015–2025)Cornelia Jäkel · Heidelberg University4 papers (2021–2025)Lorenz Uhlmann · Novartis (Switzerland)4 papers (2014–2019)Sebastian Adeberg · Goethe University Frankfurt3 papers (2023–2025)Wolfgang Wick · Heidelberger Institut für Radioonkologie3 papers (2019–2023)